Roshni Kulkarni
Pediatric Hematology-Oncology · Lansing, MINPI 1972517811
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Sanofi at 26.9% of the total. Reporting peaked in 2023 at $51,328 and has fallen 63.1% since, to $18,937 in 2024. Among pediatric hematology-oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 99 payments — averaging $1510.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$40K
- Novo Nordisk$38K
- CSL Behring$24K
- Genentech USA, Inc.$16K
- Novo Nordisk Health Care AG$9K
- Bioverativ Therapeutics Inc.$7K
- plus $16K from 8 others
Across 337 payments — averaging $1479.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bioverativ Therapeutics Inc.$229K
- Sanofi US Services Inc.$92K
- Novo Nordisk AS$66K
- Biomarin Pharmaceutical Inc.$61K
- Sanofi$33K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- plus $11K from 3 others
What the payments were for
- Consulting fees$88,42159%
- Speaking & faculty fees$48,56532%
- Travel & lodging$9,3396%
- Food & beverage$3,1732%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 25 | $40,202 |
| Novo Nordisk | 18 | $38,002 |
| CSL Behring | 10 | $24,027 |
| Genentech USA, Inc. | 22 | $15,606 |
| Novo Nordisk Health Care AG | 3 | $8,910 |
| Bioverativ Therapeutics Inc. | 5 | $7,038 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,200 |
| Sanofi-aventis U.S. LLC | 1 | $3,066 |
| Biomarin Pharmaceutical Inc. | 5 | $2,098 |
| Bayer | 1 | $1,998 |
| Shire North American Group Inc | 2 | $1,925 |
| Sanofi US Services Inc. | 1 | $1,816 |
| Pfizer | 3 | $1,309 |
| Octapharma USA, Inc. | 1 | $300 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$149,497 in reported general payments places this provider in the 95th percentile of 84 pediatric hematology-oncology providers in Michigan.
See all pediatric hematology-oncology providers in Michigan →
Other pediatric hematology-oncology in Lansing
- Shawn JobeLansing$94K
- Renuka GeraLansing$859
- David CerviLansing$155
- Steven PipeAnn Arbor$1.3M
- Angela WeyandAnn Arbor$384K
- Michael CallaghanDetroit$374K
- Jordan ShavitAnn Arbor$190K
- Ahmar ZaidiDetroit$119K
- Troy QuiggGrand Rapids$101K
- Andrew CampbellAnn Arbor$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.